Literature DB >> 8447119

Orosomucoid system: 17 additional orosomucoid variants and proposal for a new nomenclature.

I Yuasa1, S Weidinger, K Umetsu, K Suenaga, G Ishimoto, B C Eap, J C Duche, P Baumann.   

Abstract

There are two forms of orosomucoid (ORM) in the sera of most individuals. They are encoded by two separate but closely linked loci, ORM1 and ORM2. A number of variants have been identified in various populations. Duplication and nonexpression are also observed in some populations. Thus, the ORM system is very complicated and its nomenclature is very confusing. In order to propose a new nomenclature, ORM variants detected by several laboratories have been compared and characterized by isoelectric focusing (IEF) followed by immunoprinting. A total of 57 different alleles including 17 new ones were identified. The 27 alleles were assigned to the ORM1 locus, and the others to the ORM2 locus. The designations ORM*F1, ORM1*F2, ORM1*S and ORM2*M were adopted for the four common alleles instead of ORM1*1, ORM1*3, ORM1*2 and ORM2*1 (ORM2*A), respectively. The variants were designated alpha numerically according to their relative mobilities after IEF in a pH gradient of 4.5-5.4 with Triton X-100 and glycerol. For the duplicated genes a prefix is added to a combined name of two alleles, e.g. ORM1*dB9S. Silent alleles were named ORM1*Q0 and ORM2*Q0 conventionally. In addition, the effects of diseases to ORM band patterns after IEF are also discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447119     DOI: 10.1111/j.1423-0410.1993.tb02514.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  5 in total

Review 1.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Structural insights into differences in drug-binding selectivity between two forms of human alpha1-acid glycoprotein genetic variants, the A and F1*S forms.

Authors:  Koji Nishi; Tomomi Ono; Teruya Nakamura; Naoko Fukunaga; Miyoko Izumi; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Yuriko Yamagata; Stephen Curry; Masaki Otagiri
Journal:  J Biol Chem       Date:  2011-02-24       Impact factor: 5.157

3.  Tryptophan residues play an important role in the extraordinarily high affinity binding interaction of UCN-01 to human alpha-1-acid glycoprotein.

Authors:  Masaaki Katsuki; Victor Tuan Giam Chuang; Koji Nishi; Ayaka Suenaga; Masaki Otagiri
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

4.  N-glycan microheterogeneity regulates interactions of plasma proteins.

Authors:  Di Wu; Weston B Struwe; David J Harvey; Michael A J Ferguson; Carol V Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-15       Impact factor: 11.205

5.  Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9.

Authors:  Luo Qiong; Jun Yin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.